Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Cash from Investing Activities: 2009-2025

Historic Cash from Investing Activities for Cytokinetics (CYTK) over the last 17 years, with Sep 2025 value amounting to -$71.0 million.

  • Cytokinetics' Cash from Investing Activities fell 57.55% to -$71.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $198.7 million, marking a year-over-year increase of 126.66%. This contributed to the annual value of -$553.1 million for FY2024, which is 331.18% down from last year.
  • Per Cytokinetics' latest filing, its Cash from Investing Activities stood at -$71.0 million for Q3 2025, which was down 234.22% from $52.9 million recorded in Q2 2025.
  • Cytokinetics' Cash from Investing Activities' 5-year high stood at $165.5 million during Q1 2023, with a 5-year trough of -$651.5 million in Q2 2024.
  • Its 3-year average for Cash from Investing Activities is -$20.5 million, with a median of $52.9 million in 2025.
  • In the last 5 years, Cytokinetics' Cash from Investing Activities crashed by 1,118.33% in 2022 and then surged by 357.47% in 2023.
  • Quarterly analysis of 5 years shows Cytokinetics' Cash from Investing Activities stood at $47.3 million in 2021, then slumped by 38.21% to $29.2 million in 2022, then tumbled by 378.34% to -$81.4 million in 2023, then soared by 236.18% to $110.9 million in 2024, then plummeted by 57.55% to -$71.0 million in 2025.
  • Its Cash from Investing Activities stands at -$71.0 million for Q3 2025, versus $52.9 million for Q2 2025 and $106.0 million for Q1 2025.